{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:15:17Z","timestamp":1789017317670,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.omtm.2022.06.010","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T02:34:59Z","timestamp":1655865299000},"page":"207-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0639","authenticated-orcid":false,"given":"Anthony M.","family":"Battram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Oliver-Cald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bosch i Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Mart\u00ednez-Cibri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.06.010_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.omtm.2022.06.010_bib2","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.beha.2020.101141","article-title":"CAR T and CAR NK cells in multiple myeloma: expanding the targets","volume":"33","author":"Shah","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.omtm.2022.06.010_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-cells in multiple myeloma: state of the art and future directions","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtm.2022.06.010_bib4","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2022.06.010_bib5","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2022.06.010_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omtm.2022.06.010_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2022.06.010_bib8","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cancers13194787","article-title":"Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma","volume":"13","author":"Ackley","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omtm.2022.06.010_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.06.010_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2022.06.010_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omtm.2022.06.010_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune-based therapies in the management of multiple myeloma","volume":"10","author":"Zanwar","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omtm.2022.06.010_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtm.2022.06.010_bib14","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in T\u00a0cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2022.06.010_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in Multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtm.2022.06.010_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omtm.2022.06.010_bib18","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2022.06.010_bib19","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T\u00a0cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.06.010_bib20","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/cancers12102885","article-title":"Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020","volume":"12","author":"Bobin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omtm.2022.06.010_bib21","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat. Care Soc. Pract."},{"key":"10.1016\/j.omtm.2022.06.010_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjc.6690344","article-title":"Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response","volume":"80","author":"Reyes","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtm.2022.06.010_bib23","doi-asserted-by":"crossref","first-page":"e77925","DOI":"10.1371\/journal.pone.0077925","article-title":"Impaired functionality of antiviral T\u00a0cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor","volume":"8","author":"Bunse","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2022.06.010_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cei.12794","article-title":"Granulocyte colony-stimulating factor impairs CD8+ T\u00a0cell functionality by interfering with central activation elements","volume":"185","author":"Bunse","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omtm.2022.06.010_bib25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2002-04-1200","article-title":"G-CSF as immune regulator in T\u00a0cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases","volume":"102","author":"Franzke","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib26","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood.V86.12.4422.bloodjournal86124422","article-title":"Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease","volume":"86","author":"Pan","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib27","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V95.7.2269","article-title":"Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in\u00a0vitro and in\u00a0vivo","volume":"95","author":"Sloand","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib28","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2003-08-2864","article-title":"Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T\u00a0cells and promotes transplantation tolerance","volume":"103","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2018.10.004","article-title":"Manufacture of chimeric antigen receptor T\u00a0cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion","volume":"25","author":"K\u00fcnkele","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2022.06.010_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T\u00a0cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.06.010_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3324\/haematol.2019.228577","article-title":"Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma","volume":"106","author":"Perez-Amill","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2022.06.010_bib32","doi-asserted-by":"crossref","first-page":"e003783","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtm.2022.06.010_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/ph13110406","article-title":"Contrasting immunopathogenic and therapeutic roles of granulocyte colony-stimulating factor in cancer","volume":"13","author":"Theron","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtm.2022.06.010_bib34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1152\/ajpcell.00387.2003","article-title":"Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-\u03b1 production","volume":"286","author":"Nishiki","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omtm.2022.06.010_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T\u00a0cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtm.2022.06.010_bib36","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.3390\/ijms21124346","article-title":"Senescence in the development and response to cancer with immunotherapy: a double-edged sword","volume":"21","author":"Battram","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2022.06.010_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T\u00a0cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.06.010_bib38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.06.010_bib39","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1182\/blood-2008-07-167601","article-title":"Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO\/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection","volume":"113","author":"L\u00e9curoux","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib40","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.V95.8.2484","article-title":"Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells","volume":"95","author":"Arpinati","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib41","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood.V89.5.1629","article-title":"Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells","volume":"89","author":"Mielcarek","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2012.01.011","article-title":"G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells","volume":"143","author":"Luyckx","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtm.2022.06.010_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood.V92.1.215.413k10_215_222","article-title":"Production of interleukin-10 by granulocyte colony-stimulating factor- mobilized blood products: a mechanism for monocyte-mediated suppression of T- cell proliferation","volume":"92","author":"Mielcarek","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-019-0710-0","article-title":"Early myeloid-derived suppressor cells (HLA-DR-\/lowCD33+CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT","volume":"12","author":"Wang","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omtm.2022.06.010_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2009.03.509","article-title":"G-CSF induces a potentially tolerant gene and immunophenotype profile in T\u00a0cells in\u00a0vivo","volume":"132","author":"Toh","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtm.2022.06.010_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T\u00a0cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.06.010_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.06.010_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.06.010_bib49","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.06.010_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T\u00a0cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2022.06.010_bib51","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T\u00a0cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.06.010_bib52","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/cancers13143534","article-title":"IL-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omtm.2022.06.010_bib53","doi-asserted-by":"crossref","first-page":"e002866","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtm.2022.06.010_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbmt.2019.08.009","article-title":"T cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma","volume":"26","author":"Lucas","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2022.06.010_bib55","doi-asserted-by":"crossref","first-page":"e53725","DOI":"10.7554\/eLife.53725","article-title":"Quantitative analysis of how myc controls t\u00a0cell proteomes and metabolic pathways during t\u00a0cell activation","volume":"9","author":"Marchingo","year":"2020","journal-title":"Elife"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:13:01Z","timestamp":1714695181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":55,"alternative-id":["S2329050122000894"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.06.010","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}